Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
VESPER-2 VESPER-2 was a randomized, multicenter, double-blind, 28-week placebo-controlled trial that investigated the efficacy and safety of weekly berobenatide doses in adults with obesity or overweight and type 2 diabetes
"With product now available, we are proud to offer a highquality, affordable option that supports patients, prescribers, and contributes to a strong and reliable healthcare system for Canadians." Developed in partnership with Orbicular Pharmaceutical Technologies, ApoSemaglutide Injection underwent Health Canada's standard regulatory review for peptide medicines
Tyrosine kinase inhibitors (TKIs) are effective in the targeted treatment of various malignancies
however, a dedicated kidney outcome trial with semaglutide was recently stopped early for efficacy and data are awaited in 2024 [8]
US$ 20.82
US$ 22.01
US$ 25.77
US$ 26.33
US$ 21.66
US$ 26.63
US$ 20.65
US$ 25.52
US$ 20.75
